A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors.

Trial Profile

A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Glutathionarsenoxide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 30 Apr 2012 Actual patient number is 35 as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top